Cargando…

A method for confirming a third‐party assay of I‐125 seeds used for prostate implants

The purpose of this work is to describe a method and apparatus that can be used to confirm the source strength of a large number of I‐125 seeds while maintaining sterility, accuracy, reproducibility, and time efficiency. Source strengths ranging from 0.395 to 0.504 U/seed were available for this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Muryn, John S., Wilkinson, D. Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689901/
https://www.ncbi.nlm.nih.gov/pubmed/28291924
http://dx.doi.org/10.1002/acm2.12000
_version_ 1783279482153467904
author Muryn, John S.
Wilkinson, D. Allan
author_facet Muryn, John S.
Wilkinson, D. Allan
author_sort Muryn, John S.
collection PubMed
description The purpose of this work is to describe a method and apparatus that can be used to confirm the source strength of a large number of I‐125 seeds while maintaining sterility, accuracy, reproducibility, and time efficiency. Source strengths ranging from 0.395 to 0.504 U/seed were available for this study. Three different seed configurations were measured: loose, linked, and loaded needles. A third‐party 10% assay (NIST traceable) was provided. A custom stand was built out of aluminum to hold an exposure meter [Inovision (Fluke) 451P pressurized ion chamber] at 25 cm above the I‐125 sources to measure the exposure rate. The measurements were made in an operating room, and a sterile sheet was placed under the nonsterile aluminum stand on a sterile loading table. Seeds and needles were placed in a sterile tray for these measurements. Two hundred and six loose seeds in six batches (0.395, 0.395, 0.409, 0.444, 0.444, and 0.444 U/seed) and 1434 seeds in 10 batches containing various strands (0.444, 0.444, 0.444, 0.444, .0444, 0.466, 0.466, 0.504, and 0.504 U/seed) were measured. For the loose and stranded seeds, the average exposure rate per unit activity was measured to be 0.589 mR/h·U with a standard deviation of 0.017. Loaded needles were measured with an average exposure rate per unit activity to be 0.269 mR/h·U with a standard deviation of 0.014. We conclude that the method described here is capable of confirming a third‐party assay when performed on a large number of loose or stranded seeds in bulk. It is less reliable for preloaded needles.
format Online
Article
Text
id pubmed-5689901
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56899012018-04-02 A method for confirming a third‐party assay of I‐125 seeds used for prostate implants Muryn, John S. Wilkinson, D. Allan J Appl Clin Med Phys Radiation Oncology Physics The purpose of this work is to describe a method and apparatus that can be used to confirm the source strength of a large number of I‐125 seeds while maintaining sterility, accuracy, reproducibility, and time efficiency. Source strengths ranging from 0.395 to 0.504 U/seed were available for this study. Three different seed configurations were measured: loose, linked, and loaded needles. A third‐party 10% assay (NIST traceable) was provided. A custom stand was built out of aluminum to hold an exposure meter [Inovision (Fluke) 451P pressurized ion chamber] at 25 cm above the I‐125 sources to measure the exposure rate. The measurements were made in an operating room, and a sterile sheet was placed under the nonsterile aluminum stand on a sterile loading table. Seeds and needles were placed in a sterile tray for these measurements. Two hundred and six loose seeds in six batches (0.395, 0.395, 0.409, 0.444, 0.444, and 0.444 U/seed) and 1434 seeds in 10 batches containing various strands (0.444, 0.444, 0.444, 0.444, .0444, 0.466, 0.466, 0.504, and 0.504 U/seed) were measured. For the loose and stranded seeds, the average exposure rate per unit activity was measured to be 0.589 mR/h·U with a standard deviation of 0.017. Loaded needles were measured with an average exposure rate per unit activity to be 0.269 mR/h·U with a standard deviation of 0.014. We conclude that the method described here is capable of confirming a third‐party assay when performed on a large number of loose or stranded seeds in bulk. It is less reliable for preloaded needles. John Wiley and Sons Inc. 2016-11-24 /pmc/articles/PMC5689901/ /pubmed/28291924 http://dx.doi.org/10.1002/acm2.12000 Text en © 2016 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Muryn, John S.
Wilkinson, D. Allan
A method for confirming a third‐party assay of I‐125 seeds used for prostate implants
title A method for confirming a third‐party assay of I‐125 seeds used for prostate implants
title_full A method for confirming a third‐party assay of I‐125 seeds used for prostate implants
title_fullStr A method for confirming a third‐party assay of I‐125 seeds used for prostate implants
title_full_unstemmed A method for confirming a third‐party assay of I‐125 seeds used for prostate implants
title_short A method for confirming a third‐party assay of I‐125 seeds used for prostate implants
title_sort method for confirming a third‐party assay of i‐125 seeds used for prostate implants
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689901/
https://www.ncbi.nlm.nih.gov/pubmed/28291924
http://dx.doi.org/10.1002/acm2.12000
work_keys_str_mv AT murynjohns amethodforconfirmingathirdpartyassayofi125seedsusedforprostateimplants
AT wilkinsondallan amethodforconfirmingathirdpartyassayofi125seedsusedforprostateimplants
AT murynjohns methodforconfirmingathirdpartyassayofi125seedsusedforprostateimplants
AT wilkinsondallan methodforconfirmingathirdpartyassayofi125seedsusedforprostateimplants